(More on government funded inventions here. Other KEI comments on NIH licenses are found here.) Sabarni K. Chatterjee, Ph.D., M.B.A. Senior Licensing and Patenting Manager, NCI Technology Transfer Center, 9609 Medical Center Drive, RM 1E530 MSC 9702, Bethesda, MD 20892-9702… Continue Reading
In a sternly worded letter dated 18 February 2016, the Biotechnology Innovation Organization (BIO), the National Association of Manufacturers (NAM), the National Foreign Trade Council (NFTC), the Pharmaceutical Research and Manufacturers of America (PhRMA), the U.S. Chamber of Commerce (the Chamber) and the United States Council for International Business (USCIB) wrote Senator Orrin Hatch (Republican – Utah) expressing serious reservations with the United Nations High-Level Panel on Access to Medicines (UN HLP). Continue Reading
GSK has made a major announcement of new policies to expand access to its patented medicines. A copy of the press statement is here. Continue Reading
On March 28, 2016, six Senators and six members of the House of Representatives sent a letter to HHS Secretary Burwell and Director Collins at NIH, calling for an “open and transparent public hearing” to discuss the issues presented in… Continue Reading
In early March 2016, the World Trade Organization’s (WTO) TRIPS Council discussed “Intellectual Property and Innovation: Education and Diffusion”. The following delegations co-sponsored discussion of this item on Education and Diffusion – Australia, European Union, Switzerland, United States, Japan, Singapore, Peru, Russian Federation, Chinese Taipei and Hong Kong China.
On Thursday, 11 February 2016, five groups including Knowledge Ecology International (KEI), Oxfam, Stop AIDS, Third World Network (TWN) and Treatment Action Campaign (TAC) sent a letter to Dr. Francis Gurry, Director-General of the World Intellectual Property Organization (WIPO) highlighting our concerns with statements expressed by WIPO relating to the United Nations Secretary General’s High-Level Panel on Access to Medicines (HLP). To date, we have yet to hear any formal response from WIPO. Continue Reading
Attached below are the four submissions for which KEI was the lead author to the UN Secretary General’s High Level Panel (HLP) on Access to Medicine.
Implications of the Trans Pacific Partnership (TPP) and Regional Comprehensive Economic Partnership (RCEP) on Universal Health Coverage
Knowledge Ecology International
26 January 2016
9 AM to 12:30 PM
Lotus Suite 3. 22nd Floor
Bangkok Convention Centre
Bangkok, Thailand
For more information on the 2021-2022 Xtandi request please visit: https://www.keionline.org/xtandi2021 (More on government funded inventions here.) On January 14, 2016, Knowledge Ecology International (KEI) and the Union for Affordable Cancer Treatment (UACT) submitted a request to the National Institutes… Continue Reading
Today Knowledge Ecology International and the Union for Affordable Cancer Treatment (UACT) petitioned the Department of Health and Human Services, the Department of Defense, and the National Institutes of Health, asking that they exercise either their royalty-free, non-exclusive license or federal “march-in” rights to end the monopoly on an expensive prostate cancer drug, enzalutamide, marketed as Xtandi by Astellas, a Japanese pharmaceutical company.
Xtandi was invented at UCLA on federal grants from the NIH and DoD.